Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Odyssey Health
Las Vegas, Nevada, USAodysseyhealthinc.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Odyssey Health developed a proprietary intranasal powder delivery platform and advanced two main programs—ONP‑002 (a neurosteroid therapy for concussion) and ONP‑001 (for Niemann-Pick type C Disease). Their lead asset, ONP‑002, demonstrated safety and tolerability in a completed Phase 1 trial with evidence of rapid brain distribution in preclinical models. In January 2024, Oragenics acquired these neurological assets to further clinical development into Phase 2 trials.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Small moleculeNeurosteroidDevice
- Industry
- Biotech
Beyond the preview
Go deeper on Odyssey Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Odyssey Health.